Left Atrial Appendage Closure Devices Market (2026-2032)

Left Atrial Appendage Closure Devices Market: Low Treatment Penetration, Rising Procedure Volumes and Expanding AF Ablation Use Strengthen Device Demand

The Global Left Atrial Appendage Closure Devices Market was valued at approximately USD 2.20 billion in 2025 and is projected to reach approximately USD 6.20 billion by 2032, expanding at a CAGR of around 16.0% during 2026–2032. Approximately 150,000–160,000 percutaneous left atrial appendage closure procedures were performed globally in 2025, while more than 600,000 patients had received a WATCHMAN device cumulatively by 2025. Boston Scientific generated USD 1.958 billion from WATCHMAN in 2025, establishing LAA closure as one of the largest cardiovascular implant categories outside conventional coronary stenting and structural heart valve replacement.

The clinical population remains substantially larger than annual treatment volume. At least 10.55 million U.S. adults were estimated to have diagnosed atrial fibrillation, equivalent to approximately 4.48% of the adult population. Contemporary U.S. data also show that LAA closure patients are concentrated among older and clinically complex individuals, with historical registry populations averaging approximately 76 years of age, a mean CHA₂DS₂-VASc score of 4.8 and a mean HAS-BLED score of approximately 3.0. About 70.1% had a previous bleeding history, 41.9% had gastrointestinal bleeding, 40.2% had prior stroke or transient ischemic attack, 64.3% had a history of major bleeding and 35.5% had high fall risk. These findings indicate that LAA closure demand is concentrated among patients with substantial thromboembolic risk and clinically meaningful limitations to long-term anticoagulation.

U.S. procedure activity has expanded rapidly. Medicare LAAO procedures increased from 6,069 in 2017 to 29,083 in 2021, while the number of clinicians performing the procedure increased from 293 to 1,038. Based on the research, approximately 115,000–125,000 LAA closure procedures were performed annually in the United States in 2025, compared with an estimated 2.0–2.5 million patients within the current and evolving addressable U.S. population. Annual treatment penetration therefore remained at approximately 5–6%, leaving substantial room for procedure growth even without major increases in the underlying AF population.

Anticoagulation limitations remain central to the existing patient pool. Contemporary U.S. evidence indicates approximately 30% of patients with atrial fibrillation were not receiving anticoagulant therapy, while historical LAAO registry data show that approximately seven in ten implanted patients had already experienced prior bleeding. These findings show that a substantial share of the commercially relevant population consists of patients with prior bleeding, recurrent bleeding, high fall risk, intolerance or other reasons that make long-term anticoagulation difficult to maintain.

Clinical performance has improved sufficiently to support broader treatment volumes. An analysis of approximately 87,480 WATCHMAN procedures reported overall procedural success of around 94.2%, while earlier NCDR data showed that approximately 98.1% of patients in whom a device was deployed achieved implantation with less than 5 mm residual leak. Major in-hospital adverse events in that earlier registry occurred in approximately 2.16% of procedures. More recent WATCHMAN FLX Pro surveillance included 21,589 attempted implantations between October 2023 and June 2024, showing that newer-generation devices have already reached large real-world procedural volumes.

The OPTION trial has added an important new source of procedure growth by establishing stronger evidence for LAA closure following atrial fibrillation ablation. The study enrolled approximately 1,600 patients and reported non-procedure-related major or clinically relevant nonmajor bleeding at 36 months in 8.5% of patients receiving LAA closure compared with 18.1% receiving oral anticoagulation. Following these results, the FDA expanded WATCHMAN FLX and FLX Pro indications in July 2025 for appropriate patients following catheter ablation. By September 2025, approximately 25% of U.S. WATCHMAN procedures were being performed concomitantly with AF ablation, demonstrating that the combined procedure had already become a material part of implant activity.

Abbott's Amplatzer Amulet remains the principal competing platform. The Amulet IDE trial enrolled 1,878 patients, and complete LAA occlusion was achieved in 98.9% of Amulet patients compared with 96.8% with Watchman 2.5. Five-year outcomes showed ischemic stroke or systemic embolism rates of 7.4% with Amulet and 7.1% with Watchman, major bleeding rates of 20.1% and 20.0%, and cardiovascular death rates of 14.3% and 15.4%, respectively. The close long-term outcome rates indicate that competition is increasingly determined by implantation characteristics, anatomical coverage, sealing performance and physician preference rather than major differences in long-term stroke outcomes.

Reimbursement continues to support procedure economics. For FY2025, national average Medicare inpatient payments were approximately USD 27,828 under MS-DRG 273 and USD 22,211 under MS-DRG 274, while the reimbursement level for concomitant LAA closure and cardiac ablation under MS-DRG 317 was approximately USD 44,026. This reimbursement framework is increasingly relevant as combined ablation and LAA closure procedures account for a larger proportion of implant activity.

The potential addressable population could expand further if LAA closure gains a broader role as an alternative to direct oral anticoagulants. Boston Scientific reported in March 2026 that the CHAMPION-AF study met its primary and secondary safety and efficacy endpoints, supporting regulatory submissions for broader first-line stroke-prevention use. The company has estimated an existing global WATCHMAN-addressable population of approximately 5 million patients, with potential expansion toward 20 million patients globally under broader use. Its U.S. opportunity could increase toward approximately 8 million patients, materially above the current estimated 2.0–2.5 million addressable population. Boston Scientific's 2025 Investor Day similarly characterized WATCHMAN as competing in an approximately USD 2 billion served market growing at around 20%.

Endocardial LAA Closure Devices Account for the Majority of Market Revenue

By device type, endocardial LAA closure devices represented approximately USD 2.02 billion of the USD 2.20 billion market in 2025, accounting for roughly 92% of global revenue, according to the findings. This segment is led by WATCHMAN FLX, WATCHMAN FLX Pro and Amplatzer Amulet, which together account for the overwhelming majority of commercially implanted percutaneous closure devices. Epicardial and alternative closure approaches represented an estimated USD 180 million market in 2025, with adoption concentrated in more selective surgical or hybrid treatment pathways.

Standalone LAA Closure Remains Largest, but Concomitant Ablation Procedures Are Expanding Faster

By procedure type, standalone LAA closure accounted for approximately USD 1.67 billion in 2025, representing about 76% of the global market, while concomitant or sequential closure associated with AF ablation represented approximately USD 530 million. The latter segment is expanding more quickly as electrophysiology practices integrate stroke prevention into AF ablation pathways. Research findings show that approximately 25% of U.S. WATCHMAN cases were already performed concomitantly with ablation by September 2025, and the proportion is expected to increase further through 2028.

Hospitals and Integrated Cardiovascular Centers Dominate Device Utilization

By end user, hospitals and integrated cardiovascular centers represented approximately USD 1.85 billion of market revenue in 2025, or around 84% of the total market, according to the analysis. Dedicated cardiac catheterization and electrophysiology laboratories accounted for approximately USD 290 million, while ambulatory and other specialized facilities represented approximately USD 60 million. Most LAA closure implants remain concentrated in hospital-based programs because the treated population is predominantly older and clinically complex, while the procedure requires transseptal access, procedural imaging and specialized electrophysiology or structural-heart capabilities.

WATCHMAN Holds Nearly Nine-Tenths of the Commercial Market

By major device platform, WATCHMAN's reported USD 1.958 billion in 2025 revenue represented approximately 89% of the estimated global LAA closure devices market, while Amulet and other competing platforms collectively accounted for an estimated USD 240 million. The findings indicate that Boston Scientific's established implant base, extensive clinical evidence and physician training network continue to support its market leadership, while Amulet remains the principal large-scale competing platform.

Procedure Growth Remains the Most Important Revenue Indicator Through 2032

The USD 2.20 billion market in 2025 is projected to reach approximately USD 6.20 billion by 2032, while current annual global procedure volume remains approximately 150,000–160,000 cases. According to the findings, current implant volume still represents only a small share of the several-million-patient addressable population, supporting continued procedure expansion through 2032.

The most important quantitative indicators through 2032 are annual LAA closure procedure volume, eligible NVAF patient population, treatment penetration, AF ablation volume, concomitant procedure share, procedural success, residual leak, major bleeding outcomes, implanting-center capacity, reimbursement per procedure and the size of the population that could become eligible if LAA closure expands beyond patients unable to remain on long-term anticoagulation.

Methodology note: The USD 2.20 billion global market, USD 6.20 billion 2032 forecast, annual procedure volumes, current addressable patient population, treatment penetration and segment-level market values are based on the findings and research analysis. Manufacturer revenue, WATCHMAN cumulative implant numbers, epidemiological statistics, clinical trial outcomes, registry results, regulatory approvals and reimbursement values are externally reported figures.